Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant
American Journal of Medical Genetics Part A · 2026
DOI: 10.1002/ajmga.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Lauren G Banaszak und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Neoplasms, Telomere, DNA Helicases. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Robert and Kate Niehaus Center for Inherited Cancer Genomics.
Themen: Onkologische Pflege
Abstract (Originalsprache)
RTEL1 R1264H is a founder variant with a carrier frequency of 0.3%–1.0% in the Ashkenazi Jewish population. While biallelic RTEL1 R1264H causes a severe form of telomere biology disorder (TBD) presenting in childhood, the clinical significance of monoallelic carrier status has remained uncertain, limiting effective counseling and management. Here, we describe the clinical features, telomere lengths, and tumor somatic profiles of cancer patients found to be heterozygous for RTEL1 R1264H to evaluate for evidence of subclinical TBD in this population. Among 39,337 individuals who underwent RTEL1 germline analysis via MSK‐IMPACT, 32 (0.08%) were incidentally found to be heterozygous for RTEL1 R1264H. Three individuals (9%) met diagnostic criteria for TBD based on compatible clinical features and telomere shortening, and two additional individuals (6%) had histories suspicious for TBD but did not have telomere length data available. Notably, 7 individuals (22%) experienced severe or fatal therapy‐related toxicities, despite many lacking other clinical features of a TBD. These findings support that RTEL1 R1264H can act in an autosomal dominant fashion and confer TBD disease risk, albeit with low penetrance, and may increase susceptibility to treatment‐related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Regeneron, New York, New York, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
ORCID-Profile: Lauren G Banaszak, Ying Liu, Alicia Latham
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Robert and Kate Niehaus Center for Inherited Cancer Genomics
Zitieren
APA
Banaszak, L. G., Fiala, E., Ceyhan-Birsoy, O., Khurram, A., Kemel, Y. M., Walsh, M. F., Liu, Y., Carlo, M., Latham, A., Murciano-Goroff, Y. R., Abbass, M. A., Berger, M., Petrini, J. H. J., Mandelker, D., Offit, K., & Stadler, Z. K. (2026). Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmga.70032
Vancouver
Banaszak LG, Fiala E, Ceyhan-Birsoy O, Khurram A, Kemel YM, Walsh MF, et al. Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmga.70032
BibTeX
@article{Banaszak2026,
author = {Banaszak, Lauren G and Fiala, Elise and Ceyhan-Birsoy, Ozge and Khurram, Aliya and Kemel, Yelena M and Walsh, Michael F and Liu, Ying and Carlo, Maria and Latham, Alicia and Murciano-Goroff, Yonina R and Abbass, Mohammad Ali and Berger, Micheal and Petrini, John H J and Mandelker, Diana and Offit, Kenneth and Stadler, Zsofia Kinga},
title = {Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
doi = {10.1002/ajmga.70032}
}
EUVIMED